A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations and Change in Lung Function in Patients (12-75 Years of Age) With Eosinophilic Asthma
This study is ongoing, but not recruiting participants.
Study NCT01287039
Information provided by Teva Pharmaceutical Industries
First Received on January 28, 2011.
Last Updated on June 17, 2013
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
